12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Company News  |  Deals

Celgene, OncoMed deal

OncoMed granted Celgene exclusive options to jointly develop and commercialize up to six of OncoMed's cancer stem cell products, including demcizumab ( OMP-21M18). OncoMed will receive $155 million in cash up front. Celgene also will purchase about $22.3 million in OncoMed shares in a private placement, or about a 5% stake. OncoMed is eligible for up to $3.1 billion in option exercises and milestones for the six programs, including $790 million for demcizumab alone, plus royalties.

Celgene can exercise its...

Read the full 388 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >